Development of a PBPK Model for Mesalamine Using ACATPlus to Support Prediction of Local Gut Tissue Exposure

Development of a PBPK Model for Mesalamine Using ACATPlus to Support Prediction of Local Gut Tissue Exposure

Conference: DMDG
Software: GastroPlus®

Mesalamine is a locally acting anti-inflammatory drug used to treat inflammatory bowel disease, where efficacy depends on achieving adequate concentrations in the terminal ileum and colonic tissues.

Dose Optimization of Cefazolin for Pediatric Patients with Renal Impairment Using Physiologically Based Pharmacokinetic Modeling (PBPK) in GastroPlus

Dose Optimization of Cefazolin for Pediatric Patients with Renal Impairment Using Physiologically Based Pharmacokinetic Modeling (PBPK) in GastroPlus

Publication: Pharmaceutics
Software: GastroPlus®

Cefazolin is a first-generation cephalosporin antibiotic widely used for the treatment and prophylaxis of bacterial infections in both adult and pediatric populations.

Physiologically Based Pharmacokinetic Modelling and Dose Optimization of Tedizolid in Paediatric Patients

Physiologically Based Pharmacokinetic Modelling and Dose Optimization of Tedizolid in Paediatric Patients

Publication: British Journal of Clinical Pharmacology
Software: GastroPlus®

Tedizolid is a next-generation oxazolidinone antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs).

Understanding Pharmacokinetic Variability of Pomalidomide: A Physiologically Based Pharmacokinetic Analysis of Disease-Related Physiology, Ethnicity, Hepatic Impairment, Food Effects, Drug Interactions, and Smoking

Understanding Pharmacokinetic Variability of Pomalidomide: A Physiologically Based Pharmacokinetic Analysis of Disease-Related Physiology, Ethnicity, Hepatic Impairment, Food Effects, Drug Interactions, and Smoking

Publication: Clinical Pharmacokinetics
Software: GastroPlus®

Understanding interindividual pharmacokinetic variability and potential for drug interactions is of clinical importance for pomalidomide given its long-term use in patients with relapsed and/or refractory multiple myeloma (RRMM).

Navigating Surfactant Selection in In Vitro Dissolution Testing: Mechanistic Insights and Practical Strategies

Navigating Surfactant Selection in In Vitro Dissolution Testing: Mechanistic Insights and Practical Strategies

Publication: AAPS PharmSciTech

In vitro dissolution testing is central to pharmaceutical development, yet it is increasingly challenged by poorly soluble drugs, which account for over 40% of marketed products and up to 90% of new chemical entities, for which dissolution often limits absorption.

A Curated Benchmark Database for High-Throughput Mechanistic Pharmacokinetic Prediction

A Curated Benchmark Database for High-Throughput Mechanistic Pharmacokinetic Prediction

Publication: J Pharmacokinet Pharmacodyn
Software: ADMET Predictor®

The evaluation of a drug candidate's pharmacokinetic (PK) properties, while critical for the success of a drug, has traditionally been excluded from the early drug development process, in large part due to the cost of assays and the difficulty predicting PK properties from structures.

Exploring Avenues of Predicting Drug-Induced Liver Injury

Exploring Avenues of Predicting Drug-Induced Liver Injury

Authors: Liyanarachchi DP
Publication: Chem Res Toxicol
Software: DILIsym®

Drug-induced liver injury (DILI) is a major cause of acute liver dysfunction and remains one of the most challenging adverse drug reactions encountered in clinical practice.

Sustained Drug Exposure Drives Efficacy in Mice: PK/PD Analysis of Corallopyronin A against Wolbachia using Physiologically Based Absorption Modeling

Sustained Drug Exposure Drives Efficacy in Mice: PK/PD Analysis of Corallopyronin A against Wolbachia using Physiologically Based Absorption Modeling

Publication: Eur J Pharm Sci
Software: GastroPlus®

Corallopyronin A (CorA) depletes essential Wolbachia endosymbionts of filarial nematodes and is therefore a promising candidate for treating the neglected tropical diseases lymphatic filariasis and onchocerciasis.

Toxicity of Some Natural Products in the Treatment of Rheumatoid Arthritis

Toxicity of Some Natural Products in the Treatment of Rheumatoid Arthritis

Publication: Life 2026

Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects mainly peripheral joints because of inflammation of the synovial membrane.